Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JACI 35.054

Next Previous
X
Search
Drug Profile

JACI 35.054

Alternative Names: JACI-35.054

Latest Information Update: 18 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AC Immune
  • Developer AC Immune; Johnson & Johnson Innovative Medicine
  • Class Alzheimer vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 05 Sep 2023 AC Immune and Janssen Research & Development completes a phase-I/II trial in Alzheimer's disease (Combination therapy, Early-stage disease, In adults, In the elderly) in Netherlands, United Kingdom, Finland, Sweden (Parenteral) (NCT04445831) (EudraCT2018-004573-27)
  • 29 Nov 2022 Safety and immunogenicity data from a phase I/II trial in Alzheimer's disease released by AC Immune
  • 22 Nov 2022 Discontinued - Phase-I/II for Alzheimer's disease (Combination therapy, Early-stage disease, In the elderly, In adults) in Finland (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top